T. Rowe Price Investment Management Inc. Trims Position in Hologic, Inc. $HOLX

Key Points

• T. Rowe Price Investment Management Inc. has reduced its stake in Hologic, Inc. by 1.4%, now owning approximately 17.7 million shares valued at about $1.09 billion.
• Hologic reported an EPS of $1.08 for the last quarter, exceeding analyst estimates, while revenue increased by 1.2% year-over-year.
• Several institutional investors, including Victory Capital Management and Invesco, have increased their holdings in Hologic during the first quarter.

T. Rowe Price Investment Management Inc. lowered its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 1.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,688,478 shares of the medical equipment provider's stock after selling 250,355 shares during the period. Hologic accounts for approximately 0.7% of T. Rowe Price Investment Management Inc.'s portfolio, making the stock its 26th largest position. T. Rowe Price Investment Management Inc. owned 7.94% of Hologic worth $1,092,618,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Zions Bancorporation National Association UT acquired a new position in shares of Hologic during the first quarter worth $34,000. Allworth Financial LP grew its stake in shares of Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after purchasing an additional 216 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Hologic during the first quarter worth $42,000. Larson Financial Group LLC grew its stake in shares of Hologic by 6,016.7% during the first quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock worth $45,000 after purchasing an additional 722 shares in the last quarter. Finally, Raiffeisen Bank International AG acquired a new position in shares of Hologic during the fourth quarter worth $49,000. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Stock Performance

Shares of NASDAQ:HOLX traded up $1.09 on Friday, reaching $68.26. The company's stock had a trading volume of 1,545,907 shares, compared to its average volume of 1,851,908. The stock's 50-day moving average is $65.90 and its two-hundred day moving average is $62.49. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.39. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The stock has a market capitalization of $15.18 billion, a P/E ratio of 28.32, a PEG ratio of 2.44 and a beta of 0.49.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. During the same period in the prior year, the company earned $1.06 earnings per share. The business's revenue was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on HOLX. Royal Bank Of Canada upgraded shares of Hologic from a "sector perform" rating to an "outperform" rating and boosted their target price for the stock from $72.00 to $87.00 in a research note on Wednesday, August 6th. Mizuho set a $75.00 price target on shares of Hologic in a research report on Thursday, July 31st. Wall Street Zen raised shares of Hologic from a "hold" rating to a "buy" rating in a research report on Friday. Needham & Company LLC reissued a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Finally, Morgan Stanley boosted their price target on shares of Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a research report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have assigned a Hold rating to the company's stock. According to MarketBeat.com, Hologic currently has an average rating of "Moderate Buy" and a consensus price target of $78.00.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.